SCHEMBL4516554

SCHEMBL4516554

N=C(c1ccc(Br)cc1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CYP2A6 P11509 1/20 0.38
GSK3B P49841 2/20 0.37
ALOX15 P16050 1/20 0.36
KCNJ11 Q14654 1/20 0.36
OGG1 O15527 1/20 0.35
LMNA P02545 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5014652 0.88 CES1 (0.48) CES2CES1CA1CA2GSK3B
SCHEMBL16665582 0.78 PLOD2 (0.45) CES2CES1CA1CA2KCNJ11
SCHEMBL10247238 0.76 ALDH1A1 (0.46) CES2CES1CA2GSK3BKCNJ11
SCHEMBL28331909 0.76 CES2 (0.54) CES2CES1GSK3BIDO1
SCHEMBL24684593 0.73 ESR1 (0.52) CES2CES1GSK3B
SCHEMBL17216 0.71 CES1 (0.60) CES2CES1CA1CA2GSK3B
SCHEMBL16650 0.71 CES2 (0.42) CES2CES1CA1CA2CYP2A6
SCHEMBL12198147 0.71 PRSS1 (0.55) CES2CES1CA1CA2LMNA
SCHEMBL20794341 0.69 CA1 (0.53) CA1CA2MAPTHTTTDP1
SCHEMBL691536 0.68 CES2 (0.62) CES2CES1CA1CA2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110437230-B Tertiary amine compound, diphosphine ligand, intermediate and preparation method thereof 中国科学院上海有机化学研究所 2022-06-21 CN disclosed
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US disclosed
EP-1893562-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B Merck Frosst Canada Ltd. (CA) 2008-03-05 EP disclosed
US-7154005-B2 Synthesis of alpha fluoroalkyl amines MERCK FROSST CANADA, LTD. (CA) 2006-12-26 US disclosed
WO-2006133559-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B MERCK FROSST CANADA LTD. (CA) 2006-12-21 WO disclosed
US-20060052642-A1 Synthesis of alpha fluoroalkyl amines MERCK CANADA INC. (CA) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MAOB, MAOA, XDH CES2 135/4885CES1 512/4885CA1 2210/4885
US-20060052642-A1 Synthesis of alpha fluoroalkyl amines ADH5, ADH1C, INMT CES2 227/4885CES1 527/4885CA1 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.